-

Palleon Announces Issuance of a U.S. Patent for Use of Antibody Sialidase Conjugates

- Patent valid through 2037 and, with additional applications, provides broad coverage for the company’s EAGLE Sialidase platform –

WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced that the U.S. Patent and Trademark Office has issued Patent No.11,459,398 titled, “Conjugates for Targeted Cell Surface Editing.” The patent broadens Palleon’s intellectual property position and bolsters coverage for the company’s proprietary EAGLE platform, which is based on engineered human sialidase enzymes that restore antitumor immunity by degrading immunosuppressive sialoglycans on tumors and across immune cell types.

The patented technology is part of an exclusive license Palleon has with Stanford University and originated in the laboratory of Carolyn Bertozzi, an inventor on the patent, and a scientific co-founder of Palleon Pharmaceuticals. Dr. Bertozzi was recently awarded the 2022 Nobel Prize for Chemistry for the invention of bioorthogonal chemistry, a technology which enabled the foundational science for Palleon’s platform.

“It is thrilling to see Palleon’s pioneering EAGLE platform reach this important milestone,” said Dr. Bertozzi. “Therapeutic removal of sialic acid from cells in the tumor microenvironment, as this patent describes, has shown promising potential in generating an immune antitumor response in pre-clinical studies. This glyco-immunology approach could deliver meaningful benefits for patients who don’t respond to today’s immuno-oncology treatments.”

The EAGLE platform enables the development of first-in-class therapies that strip sialic acids from both immune cells and cancer cells, restoring innate and adaptive antitumor immunity. This patent covers the use in cancer of tumor-targeted antibodies conjugated to sialidase, an enzyme that cleaves sialic acid.

“This patent provides important additional intellectual property coverage for an approach that, we believe, is key to expanding the promise of immunotherapy to millions of patients, especially to those patients with immune suppression who do not respond to currently approved immunotherapy agents,” said Jim Broderick, M.D., Chief Executive Officer and founder of Palleon. “With this patent solidified, we are in a strong position to continue development of an entirely new class of investigational therapies within our rich, clinical-stage pipeline.”

About Palleon Pharmaceuticals
Palleon Pharmaceuticals is a biotechnology company pioneering glyco-immunology drug development to transform the treatment of cancer and inflammatory diseases. The Company’s proprietary platforms overcome technical barriers unique to glycobiology to enable drug discovery, patient selection, and indication prioritization to de-risk clinical development. The company’s lead program in oncology, E-602, is a Phase 1/2, first-in-class, glyco-immune checkpoint inhibitor which restores antitumor immunity by enzymatically degrading immunosuppressive sialoglycans on hypersialylated tumors and immune cells. Palleon has a rich pipeline of additional drug candidates including several assets advancing toward IND-enabling studies. The scientific co-founder of Palleon Pharmaceuticals, Carolyn Bertozzi, Ph.D, is the Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences and professor in the Department of Chemistry at Stanford University and the recipient of the 2022 Nobel Prize in Chemistry.

Contacts

Media
Thomas Stephenson
Ten Bridge Communications
thomas@tenbridgecommunications.com
(857) 244-0246

Palleon Pharmaceuticals


Release Versions

Contacts

Media
Thomas Stephenson
Ten Bridge Communications
thomas@tenbridgecommunications.com
(857) 244-0246

More News From Palleon Pharmaceuticals

Palleon Pharmaceuticals Presents Phase 2 Results for HLX79/E-602 in Primary Membranous Nephropathy at ACR Convergence 2026

WATERTOWN, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a clinical-stage biotechnology company developing glycan editing therapeutics for autoimmune disease and cancer, today announced early proof-of-concept data for its first-in-class sialidase-Fc fusion protein HLX79/E-602 (efgitasialase alfa) in primary membranous nephropathy (pMN). The results were presented in an oral session at the American College of Rheumatology (ACR) Convergence 2026 in Orlando. Palleon’s partner, Shanghai Henlius...

Palleon Pharmaceuticals Presents Phase 2 Results for HLX79/E-602 in Primary Membranous Nephropathy at ASN Kidney Week 2026

WATERTOWN, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a clinical-stage biotechnology company developing glycan editing therapeutics for autoimmune disease and cancer, today announced Phase 2 results for HLX79/E-602 (efgitasialase alfa), a first-in-class sialidase-Fc fusion protein, in primary membranous nephropathy (pMN). The data were presented today in a late-breaking oral session at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver. The randomized Phase 2 trial (NCT07...

Palleon Pharmaceuticals Announces Oral Presentation of Interim Phase 2 trial data for HLX79/E-602 in Membranous Nephropathy at the 2026 American College of Rheumatology (ACR) Convergence

WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a clinical-stage biotechnology company developing novel therapeutics for autoimmunity and cancer, will deliver an oral presentation at the 2026 American College of Rheumatology (ACR) Convergence, taking place November 6-11 in Orlando, Florida. Palleon's presentation will take place on Wednesday, November 11. Details of Palleon's Presentation: American College of Rheumatology (ACR) Convergence Title: Rapid and deep clinical responses to H...
Back to Newsroom